Logo

Xantos to Use OriGene cDNA Clones for High-Throughput Screening

Aug 16, 2004

NEW YORK, Aug. 16 (GenomeWeb News) - OriGene Technologies said that German drug discovery firm Xantos Biomedicine has acquired access to OriGene's TrueClone collection of non-redundant, full-length human cDNA clones. Xantos will use its high-throughput cellular screening technology, XantoScreen, along with the clone collection to identify and functionally validate novel targets, the company said.

 

Financial terms of the deal were not disclosed.

Breaking News
The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.